Paolo Fraticelli
Overview
Explore the profile of Paolo Fraticelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoffmann-Vold A, Maher T, Philpot E, Ashrafzadeh A, Barake R, Barsotti S, et al.
Lancet Rheumatol
. 2024 Jan;
2(2):e71-e83.
PMID: 38263663
Background: Systemic sclerosis-associated interstitial lung disease (ILD) carries a high mortality risk; expert guidance is required to aid early recognition and treatment. We aimed to develop the first expert consensus...
2.
Bettiol A, Urban M, Padoan R, Groh M, Lopalco G, Egan A, et al.
Lancet Rheumatol
. 2024 Jan;
5(12):e707-e715.
PMID: 38251561
Background: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort...
3.
Piga M, Fraticelli P, Antonicelli L, Garritani M, Ghirelli G, Martini M, et al.
Front Immunol
. 2023 Dec;
14:1325299.
PMID: 38090592
The pathogenic role of p-ANCA in eosinophilic granulomatosis with polyangiitis (EGPA) is a long-standing matter of debate. In this work, we report our real-life experience with EGPA patients, treated with...
4.
Rubenstein E, Maldini C, Vaglio A, Bello F, Bremer J, Moosig F, et al.
J Rheumatol
. 2023 Sep;
50(11):1446-1453.
PMID: 37739478
Objective: Previous studies suggested that distinct phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA; formerly known as Churg-Strauss syndrome) could be determined by the presence or absence of antineutrophil cytoplasmic antibodies...
5.
Molina B, Padoan R, Urban M, Novikov P, Caminati M, Taille C, et al.
Ann Rheum Dis
. 2023 Sep;
82(12):1587-1593.
PMID: 37734881
Background: Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations. When immunosuppressants and/or mepolizumab are ineffective, dupilumab could be an option....
6.
Quartuccio L, Bortoluzzi A, Scire C, Marangoni A, Del Frate G, Treppo E, et al.
Clin Rheumatol
. 2022 Oct;
42(2):641-642.
PMID: 36264401
No abstract available.
7.
Quartuccio L, Bortoluzzi A, Scire C, Marangoni A, Del Frate G, Treppo E, et al.
Clin Rheumatol
. 2022 Sep;
42(2):359-370.
PMID: 36169798
Cryoglobulinemic vasculitis (CV) or mixed cryoglobulinemic syndrome (MCS) is a systemic small-vessel vasculitis characterized by the proliferation of B-cell clones producing pathogenic immune complexes, called cryoglobulins. It is often secondary...
8.
Vacchi C, Testoni S, Visentini M, Zani R, Lauletta G, Gragnani L, et al.
Clin Exp Rheumatol
. 2022 Jul;
41(4):787-791.
PMID: 35894064
Objectives: Mixed cryoglobulinaemic vasculitis (MCV) is an immune-complex-mediated systemic vasculitis characterised by heterogeneous clinical manifestations mainly involving lymphatic system, skin, kidney and peripheral nervous system. Although MCV patients have been...
9.
Bettiol A, Urban M, Dagna L, Cottin V, Franceschini F, Del Giacco S, et al.
Arthritis Rheumatol
. 2021 Aug;
74(2):295-306.
PMID: 34347947
Objective: Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In...
10.
Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis
Scarpato S, Sebastiani M, Quartuccio L, Marson P, Fraticelli P, Castelnovo L, et al.
Clin Exp Rheumatol
. 2021 May;
39 Suppl 129(2):149-154.
PMID: 33938790
People with cryoglobulinaemic vasculitis (CV) have an increased risk of infections, attributed to different causes: impairment of the immune system due to the disease itself, comorbidities, and immunosuppressive therapy. Therefore,...